Skip to main content
Premium Trial:

Request an Annual Quote

NEWSBRIEF: Paradigm Genetics Sees Revenue Upswing, Increased Losses

SAN FRANCISCO, May 1 - Paradigm Genetics today posted an 8 percent increase in revenue and widened net losses in its first quarter.


Total revenue for the first quarter ended March 31 came in at $5.9 million compared with $5.4 million one year ago. The company said the revenue rise was from the sale of herbicide assays developed in collaboration with Bayer.


Net loss for the quarter increased to $5.2 million, or $.16 per common share, compared with $4 million, or $.15 a share, for the year-ago period, according to the company.


R&D spending increased to $8.1 million compared to $6.4 million for the first quarter in 2001.


Paradigm Genetics said it had roughly $8.3 million in cash, cash equivalents, and short-term investments as of March 31.


Click here for more information.


The Scan

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.

Study Looks at Parent Uncertainties After Children's Severe Combined Immunodeficiency Diagnoses

A qualitative study in EJHG looks at personal, practical, scientific, and existential uncertainties in parents as their children go through SCID diagnoses, treatment, and post-treatment stages.

Antimicrobial Resistance Study Highlights Key Protein Domains

By screening diverse versions of an outer membrane porin protein in Vibrio cholerae, researchers in PLOS Genetics flagged protein domain regions influencing antimicrobial resistance.

Latent HIV Found in White Blood Cells of Individuals on Long-Term Treatments

Researchers in Nature Microbiology find HIV genetic material in monocyte white blood cells and in macrophages that differentiated from them in individuals on HIV-suppressive treatment.